Page last updated: 2024-11-12

leupyrrin a1

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

leupyrrin A1: from myxobacterium Sorangium cellulosum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10908784
CHEMBL ID510851
MeSH IDM0460933

Synonyms (2)

Synonym
leupyrrin a1
CHEMBL510851
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID356418Antifungal activity against Rhodotorula glutinis2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
AID356423Inhibition of DNA synthesis in Rhodotorula glutinis assessed as inhibition of [methyl-3H]thymine incorporation at 2.5 ug/mL after 30 mins2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
AID356417Antifungal activity against Candida albicans2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
AID356420Antifungal activity against Botrytis cinerea2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
AID356424Inhibition of RNA synthesis in Rhodotorula glutinis assessed as inhibition of [2-14C]uracil incorporation at 2.5 ug/mL after 30 mins2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
AID356419Antifungal activity against Aspergillus niger2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
AID356422Cytotoxicity against mouse L929 cells2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
AID356425Inhibition of protein synthesis in Rhodotorula glutinis assessed as inhibition of [U-14C]protein hydrolysate incorporation at 2.5 ug/mL after 30 mins2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
AID356421Antifungal activity against Mucor hiemalis2003Journal of natural products, Sep, Volume: 66, Issue:9
The leupyrrins: a structurally unique family of secondary metabolites from the myxobacterium Sorangium cellulosum.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's5 (71.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.75 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.83 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (14.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]